• presentation

March 28, 2025

DurAVR® THV Clinical Data Update at Sydney Valves

At Sydney Valves, Dr. Rishi Puri presented data from DurAVR® THV clinical experience, demonstrating a favorable hemodynamic profile for 37 patients sustained to 1-year follow-up. 


One-year Results Highlights:

  • DurAVR® THV demonstrated a favorable hemodynamic profile sustained to one-year, with an Effective Orifice Area (EOA) of 2.1 ± 0.2 cm2, a Mean Pressure Gradient (MPG) of 8.6 ± 2.6 mmHg and Doppler Velocity Index (DVI) of 0.58.
  • At one-year, clinical safety outcomes show positive results with no valve or cardiovascular related mortality and, importantly, no prosthesis-patient mismatch (PPM) reported in these small annuli patients (aortic annulus area 395.80 ± 37.26mm2).

 

“The one-year data for DurAVR® THV continues to validate its groundbreaking hemodynamic performance, demonstrating sustained excellent effective orifice area (EOA) and low mean gradients. Most notably, this is the only transcatheter valve to show zero prosthesis-patient mismatch (PPM) in small annuli patients—an achievement that sets a new standard in TAVR. PPM is a well-established predictor of valve failure and disease progression, and eliminating it has profound implications for long-term patient outcomes. These results reinforce the transformative potential of DurAVR® as we move toward pivotal trials.” - Christopher Meduri, Anteris Chief Medical Officer